Table 2.
LC–MS analysis identified tryptic and chymotryptic peptides of microbially derived PMI
| Matched residue position | Experimental massa | Theoretical massb | Identified peptide sequence |
|---|---|---|---|
| Trypic peptides | |||
| 6–18 | 1478.749 | 1478.752 | LINSVQNYAWGSK |
| 19–45 | 2988.382 | 2988.382 | TALTELYGMENPSSQPMAELWMGAHPK |
| 50–61 | 1241.670 | 1241.673 | VQNAAGDIVSLR |
| 50–68 | 2028.047 | 2028.049 | VQNAAGDIVSLRDVIESDK |
| 62–68 | 804.3834 | 804.3865 | DVIESDK |
| 62–78 | 1773.938 | 1773.936 | DVIESDKSTLLGEAVAK |
| 69–78 | 987.5575 | 987.560 | STLLGEAVAK |
| 79–88 | 1252.696 | 1252.697 | RFGELPFLFK |
| 80–88 | 1096.593 | 1096.596 | FGELPFLFK |
| 89–104 | 1773.953 | 1773.956 | VLCAAQPLSIQVHPNK |
| 89–113 | 2757.437 | 2757.438 | VLCAAQPLSIQVHPNKHNSEIGFAK |
| 105–113 | 1001.490 | 1001.493 | HNSEIGFAK |
| 114–126 | 1343.613 | 1343.614 | ENAAGIPMDAAER |
| 182–197 | 1807.901 | 1807.903 | LSELFASLLNMQGEEK |
| 200–205 | 627.4302 | 627.4319 | ALAILK |
| 206–220 | 1714.829 | 1714.828 | SALDSQQGEPWQTIR |
| 283–294 | 1372.757 | 1372.76 | YIDIPELVANVK |
| 295–309 | 1682.935 | 1682.936 | FEAKPANQLLTQPVK |
| 357–381 | 2598.362 | 2598.365 | GSQQLQLKPGESAFIAANESPVTVK |
| Chymotrypic peptides | |||
| 1–6 | 662.3427 | 662.3421 | GSMQKL |
| 7–13 | 836.3998 | 836.4028 | INSVQNY |
| 14–21 | 832.4424 | 832.4443 | AWGSKTAL |
| 14–24 | 1175.615 | 1175.619 | AWGSKTALTEL |
| 16–25 | 1081.562 | 1081.566 | GSKTALTELY |
| 26–39 | 1575.669 | 1575.67 | GMENPSSQPMAELW |
| 61–71 | 1261.651 | 1261.651 | RDVIESDKSTL |
| 61–72 | 1374.7330 | 1374.7350 | RDVIESDKSTLL |
| 72–80 | 989.5652 | 989.5658 | LGEAVAKRF |
| 73–80 | 876.4784 | 876.4817 | GEAVAKRF |
| 97–111 | 1705.849 | 1705.854 | SIQVHPNKHNSEIGF |
| 112–128 | 1819.851 | 1819.852 | AKENAAGIPMDAAERNY |
| 129–139 | 1322.697 | 1322.698 | KDPNHKPELVF |
| 145–153 | 1113.525 | 1113.528 | LAMNAFREFc |
| 151–159 | 1078.563 | 1078.566 | REFSEIVSL |
| 151–160 | 1191.648 | 1191.65 | REFSEIVSLL |
| 160–173 | 1427.766 | 1427.767 | LQPVAGAHPAIAHF |
| 161–173 | 1314.683 | 1314.683 | QPVAGAHPAIAHF |
| 174–182 | 1068.553 | 1068.556 | LQQPDAERL |
| 174–185 | 1397.714 | 1397.715 | LQQPDAERLSEL |
| 175–186 | 1431.7 | 1431.699 | QQPDAERLSELF |
| 191–201 | 1261.603 | 1261.608 | NMQGEEKSRAL |
| 202–208 | 714.4619 | 714.4639 | AILKSAL |
| 202–216 | 1641.835 | 1641.836 | AILKSALDSQQGEPW |
| 205–216 | 1344.629 | 1344.631 | KSALDSQQGEPW |
| 209–216 | 945.3804 | 945.3828 | DSQQGEPW |
| 217–221 | 629.3849 | 629.386 | QTIRL |
| 217–225 | 1105.612 | 1105.613 | QTIRLISEF |
| 222–233 | 1402.628 | 1402.629 | ISEFYPEDSGLF |
| 237–243 | 797.5352 | 797.5375 | LLNVVKL |
| 239–250 | 1317.672 | 1317.675 | NVVKLNPGEAMF |
| 239–251 | 1430.758 | 1430.759 | NVVKLNPGEAMFL |
| 251–259 | 1047.5 | 1047.503 | LFAETPHAY |
| 252–259 | 934.4155 | 934.4185 | FAETPHAY |
| 253–259 | 787.3477 | 787.3501 | AETPHAY |
| 260–275 | 1671.851 | 1671.85 | LQGVALEVMANSDNVL |
| 261–275 | 1558.765 | 1558.766 | QGVALEVMANSDNVL |
| 266–275 | 1090.493 | 1090.497 | EVMANSDNVL |
| 296–304 | 982.5428 | 982.5447 | EAKPANQLL |
| 305–314 | 1069.574 | 1069.577 | TQPVKQGAEL |
| 305–323 | 2115.058 | 2115.053 | TQPVKQGAELDFPIPVDDF |
| 305–325 | 2333.158 | 2333.158 | TQPVKQGAELDFPIPVDDFAF |
| 326–345 | 2156.096 | 2156.096 | SLHDLSDKETTISQQSAAIL |
| 346–355 | 1196.515 | 1196.517 | FCVEGDATLW |
| 356–361 | 659.3584 | 659.3602 | KGSQQL |
| 356–363 | 900.5007 | 900.5029 | KGSQQLQL |
| 362–370 | 975.5004 | 975.5025 | QLKPGESAF |
aThe experimental mass is the uncharged mass calculated from the mass to charge ratio of the observed ion
bThe theoretical mass is the in silico generated mass that matches closest to the experimental mass
cThis peptide was modified by methionine oxidation (Oxidation-M)